Sensei Biotherapeutics (NASDAQ:SNSE) Announces Earnings Results

Sensei Biotherapeutics (NASDAQ:SNSE) released its earnings results on Friday. The company reported ($3.62) earnings per share for the quarter, beating the consensus estimate of ($4.11) by $0.49, Zacks reports.

Sensei Biotherapeutics Stock Down 11.2%

Shares of SNSE traded down $1.01 during trading hours on Friday, hitting $8.01. 22,967 shares of the company were exchanged, compared to its average volume of 74,606. The company has a market cap of $10.09 million, a price-to-earnings ratio of -0.38 and a beta of 0.31. Sensei Biotherapeutics has a fifty-two week low of $5.00 and a fifty-two week high of $18.35. The firm’s fifty day moving average is $9.90 and its 200 day moving average is $8.43.

Analyst Ratings Changes

Several equities analysts have recently issued reports on SNSE shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Sensei Biotherapeutics in a report on Thursday. HC Wainwright cut shares of Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.